Skin patch T-cell Covid vaccine to be trialled in Switzerland
A British biotech firm is set to start clinical trials in Switzerland of a skin patch vaccine against Covid-19 that uses T-cells and could offer longer-lasting immunity than existing vaccines.
This content was published on
2 minutes
The Guardian/swissinfo/sb
Español
es
Suiza someterá a prueba vacuna COVID en parche cutáneo
Emergex announcedExternal link on Monday that it had received the green light from the Swiss drugs regulator to carry out initial human trials in Lausanne, starting January 3, 2022.
The company’s easy-to-administer skin patch vaccine primes T-cells – a group of immune cells that can target and destroy virus-infected cells – to remove infected cells from the body quickly after infection, thus preventing viral replication and disease.
Robin Cohen, Emergex’s chief commercial officer, told The GuardianExternal link newspaper: “This is the first time a regulator has approved a Covid vaccine to go into clinical trials whose sole purpose is to generate a targeted T-cell response in the absence of an antibody response and those T-cells look for infected cells and kill them.”
Current Covid-19 vaccines mainly generate an antibody response that wanes over time, which means people need booster shots to maintain protection against the virus. The Emergex vaccine works differently, by killing infected cells quickly. This means it could offer longer-lasting immunity – possibly for decades – and could also be better at fighting virus mutations, said Cohen.
The trial will be conducted by Blaise Genton, a professor at the University of Lausanne’s centre for primary care and public health. He said: “This exciting new scientific approach to developing a vaccine against Sars-CoV-2 addresses the need to generate a T-cell response to elicit long-term immunity.”
In all, 26 people will receive a high and a low dose of its experimental Covid-19 vaccine. Interim results from the trial are expected in June.
More
More
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
Young undocumented migrants gain easier access to vocational training
This content was published on
Rejected asylum-seekers and young undocumented migrants in Switzerland will have easier access to basic vocational training from June 1.
Migration: Swiss government wants to shorten reunification period for families
This content was published on
Family members of people temporarily admitted to Switzerland should in future be able to join them after two years instead of three.
This content was published on
2023 was a record year for the Rhaetian Railway in several respects. Never before has the narrow-gauge railway in Graubünden, eastern Switzerland, transported so many passengers and cars.
Swiss CFOs much more optimistic despite global uncertainty
This content was published on
The main concerns of business leaders in Switzerland are geopolitical uncertainty and the important trading partners Germany and China.
Record organ donation in Switzerland despite high rejection rates
This content was published on
More organ donations were recorded in Switzerland in 2023 than ever before. This was despite a high rejection rate of 58% by surviving relatives.
This content was published on
Seven years after the death of record-breaking Swiss mountain climber Ueli Steck, his estate is going to the Alpine Museum of Switzerland in Bern.
While Switzerland struggles to vaccinate, Portugal is already finished
This content was published on
Nowhere are more people vaccinated against Covid-19 than in Portugal, where 98% of over 25-year-olds have had both doses.
Vaccine alternative has limited impact on Covid campaign
This content was published on
The offer of a non-mRNA Covid vaccine in Switzerland has failed to speed up the government’s vaccination campaign, experts say.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.